| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8784925 | Advances in Radiation Oncology | 2017 | 10 Pages |
Abstract
HIMRT is more cost-efficient than CIMRT for treating prostate cancer, even when taking into account the costs related to late radiation toxicities. HIMRT enhances the value of prostate radiation when compared with CIMRT.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
K. Ranh MD MPH, Lincy S. PhD, Deborah A. MD, Thomas J. MD, J. Michael PhD, Joy Godby, Seungtaek MD, Andrew K. MD MPH, Pamela J. MD, Steven J. MD, Sean E. MD PhD, Karen E. MD MPH,